Combination of Temsirolimus and Sunitinib

TERMINATED · PHASE1, PHASE2 · Renal Cell Carcinoma

Decision was made not to attempt a lower dose

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.